Cargando…

Covid-19 and lung cancer: A greater fatality rate?

BACKGROUND: Currently there are no reported series determining the Covid-19 infected lung cancer patient´s characteristics and outcome that allow us to clarify strategies to protect our patients. In our study we determine whether exists differences in cumulative incidence and severity of Covid-19 in...

Descripción completa

Detalles Bibliográficos
Autores principales: Rogado, Jacobo, Pangua, Cristina, Serrano-Montero, Gloria, Obispo, Berta, Marino, Almudena Martín, Pérez-Pérez, Mar, López-Alfonso, Ana, Gullón, Pedro, Lara, Miguel Ángel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260554/
https://www.ncbi.nlm.nih.gov/pubmed/32505076
http://dx.doi.org/10.1016/j.lungcan.2020.05.034
_version_ 1783540340735606784
author Rogado, Jacobo
Pangua, Cristina
Serrano-Montero, Gloria
Obispo, Berta
Marino, Almudena Martín
Pérez-Pérez, Mar
López-Alfonso, Ana
Gullón, Pedro
Lara, Miguel Ángel
author_facet Rogado, Jacobo
Pangua, Cristina
Serrano-Montero, Gloria
Obispo, Berta
Marino, Almudena Martín
Pérez-Pérez, Mar
López-Alfonso, Ana
Gullón, Pedro
Lara, Miguel Ángel
author_sort Rogado, Jacobo
collection PubMed
description BACKGROUND: Currently there are no reported series determining the Covid-19 infected lung cancer patient´s characteristics and outcome that allow us to clarify strategies to protect our patients. In our study we determine whether exists differences in cumulative incidence and severity of Covid-19 infection between lung cancer patients visiting our Medical Oncology department and the reference population of our center (320,000 people), in the current epicenter of the pandemic in Europe (Madrid, Spain). We also describe clinical and demographic factors associated with poor prognosis and Covid-19 treatment outcomes. PATIENTS AND METHODS: We retrospectively reviewed 1878 medical records of all Covid-19 patients who were admitted at Hospital Universitario Infanta Leonor of Madrid between March 5, 2020 and April 7, 2020, in order to detect cumulative incidence of Covid-19 in lung cancer patients. We also described Covid-19 treatment outcome, mortality and associated risk factors using univariate and multivariate logistic regression analysis. RESULTS: 17/1878 total diagnosis in our center had lung cancer (0.9 %) versus 1878/320,000 of the total reference population (p = 0.09). 9/17 lung cancer patients with Covid-19 diagnosis died (52.3 %) versus 192/1878 Covid-19 patients in our center (p < 0.0001). Dead lung cancer patients were elderly compared to survivors: 72 versus 64.5 years old (p = 0.12). Combined treatment with hydroxychloroquine and azithromycin improves the outcome of Covid-19 in lung cancer patients, detecting only 1/6 deaths between patients under this treatment versus others treatment, with statistical significance in the univariate and multivariate logistic regression (OR 0.04, p = 0.018). CONCLUSIONS: Lung cancer patients have a higher mortality rate than general population. Combined hydroxychloroquine and azithromycin treatment seems like a good treatment option. It is important to try to minimize visits to hospitals (without removing their active treatments) in order to decrease nosocomial transmission.
format Online
Article
Text
id pubmed-7260554
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-72605542020-06-01 Covid-19 and lung cancer: A greater fatality rate? Rogado, Jacobo Pangua, Cristina Serrano-Montero, Gloria Obispo, Berta Marino, Almudena Martín Pérez-Pérez, Mar López-Alfonso, Ana Gullón, Pedro Lara, Miguel Ángel Lung Cancer Article BACKGROUND: Currently there are no reported series determining the Covid-19 infected lung cancer patient´s characteristics and outcome that allow us to clarify strategies to protect our patients. In our study we determine whether exists differences in cumulative incidence and severity of Covid-19 infection between lung cancer patients visiting our Medical Oncology department and the reference population of our center (320,000 people), in the current epicenter of the pandemic in Europe (Madrid, Spain). We also describe clinical and demographic factors associated with poor prognosis and Covid-19 treatment outcomes. PATIENTS AND METHODS: We retrospectively reviewed 1878 medical records of all Covid-19 patients who were admitted at Hospital Universitario Infanta Leonor of Madrid between March 5, 2020 and April 7, 2020, in order to detect cumulative incidence of Covid-19 in lung cancer patients. We also described Covid-19 treatment outcome, mortality and associated risk factors using univariate and multivariate logistic regression analysis. RESULTS: 17/1878 total diagnosis in our center had lung cancer (0.9 %) versus 1878/320,000 of the total reference population (p = 0.09). 9/17 lung cancer patients with Covid-19 diagnosis died (52.3 %) versus 192/1878 Covid-19 patients in our center (p < 0.0001). Dead lung cancer patients were elderly compared to survivors: 72 versus 64.5 years old (p = 0.12). Combined treatment with hydroxychloroquine and azithromycin improves the outcome of Covid-19 in lung cancer patients, detecting only 1/6 deaths between patients under this treatment versus others treatment, with statistical significance in the univariate and multivariate logistic regression (OR 0.04, p = 0.018). CONCLUSIONS: Lung cancer patients have a higher mortality rate than general population. Combined hydroxychloroquine and azithromycin treatment seems like a good treatment option. It is important to try to minimize visits to hospitals (without removing their active treatments) in order to decrease nosocomial transmission. Elsevier B.V. 2020-08 2020-05-30 /pmc/articles/PMC7260554/ /pubmed/32505076 http://dx.doi.org/10.1016/j.lungcan.2020.05.034 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Rogado, Jacobo
Pangua, Cristina
Serrano-Montero, Gloria
Obispo, Berta
Marino, Almudena Martín
Pérez-Pérez, Mar
López-Alfonso, Ana
Gullón, Pedro
Lara, Miguel Ángel
Covid-19 and lung cancer: A greater fatality rate?
title Covid-19 and lung cancer: A greater fatality rate?
title_full Covid-19 and lung cancer: A greater fatality rate?
title_fullStr Covid-19 and lung cancer: A greater fatality rate?
title_full_unstemmed Covid-19 and lung cancer: A greater fatality rate?
title_short Covid-19 and lung cancer: A greater fatality rate?
title_sort covid-19 and lung cancer: a greater fatality rate?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260554/
https://www.ncbi.nlm.nih.gov/pubmed/32505076
http://dx.doi.org/10.1016/j.lungcan.2020.05.034
work_keys_str_mv AT rogadojacobo covid19andlungcanceragreaterfatalityrate
AT panguacristina covid19andlungcanceragreaterfatalityrate
AT serranomonterogloria covid19andlungcanceragreaterfatalityrate
AT obispoberta covid19andlungcanceragreaterfatalityrate
AT marinoalmudenamartin covid19andlungcanceragreaterfatalityrate
AT perezperezmar covid19andlungcanceragreaterfatalityrate
AT lopezalfonsoana covid19andlungcanceragreaterfatalityrate
AT gullonpedro covid19andlungcanceragreaterfatalityrate
AT laramiguelangel covid19andlungcanceragreaterfatalityrate